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INTRODUCTION 
The proportion of overweight and obese individuals has increased during the last decades 1,2. 
In the European region, the prevalence of overweight and obese women aged 15 years or 
above was 52 % in 2010 (according to the WHO global infobase). Obesity is associated with 
metabolic disturbances, higher morbidity 3 and mortality 4. Obesity is a major risk factor for 
type 2 diabetes (T2DM) 5, and simultaneously with the increasing prevalence of obesity, there 
has been a rise in the incidence of T2DM 6. 
Immigrants to western societies seem to be disproportionately affected with T2DM 7-9. The 
disease occurs at an earlier age in Asian immigrants 10, and a study from Norway found an 
earlier onset also in Middle Eastern immigrants compared to the host population 11. Onset of 
T2DM at a younger age threatens both the health of the individual 12 as well as the economic 
burden 13, since it may result in more late complications.  
Maternal pre-existing diabetes increases risk of future obesity and diabetes in the offspring 14-
16. Although maternal pre-existing diabetes is undoubtedly more detrimental to the offspring’s 
health than less severe hyperglycaemia, such as gestational diabetes (GDM), the 
Hyperglycemia and Adverse Pregnancy Outcomes (HAPO) study found a continuous 
relationship between maternal glucose levels and several pregnancy outcomes 17. In utero 
exposure to any degree of hyperglycaemia may therefore influence the metabolic health and 
the growth of the foetus, and be an important risk factor for later T2DM for both the mother 18 
and her offspring 16.  
The present thesis explores ethnic differences in adiposity and weight gain during pregnancy 
and risk of maternal hyperglycaemia, which might affect the offspring’s birth weight and 
subcutaneous fat, and thereby possibly the future risk of obesity and diabetes (Figure 1). This 
thesis focuses on adiposity and diabetes, although other chronic diseases, such as 
cardiovascular disease, could have been just as relevant. 
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Figure 1. Conceptual framework of the thesis.  
If pre-pregnant adiposity, gestational weight gain, proportion of women with GDM, maternal dyslipidaemia and 
postpartum weight retention differs across ethnicity, this may explain some of the ethnic differences in future 
risk of type 2 diabetes both in the mother and in her offspring.  
1.1 MATERNAL ADIPOSITY 
Adiposity refers to excessive amounts of adipose tissue. Adipose tissue is mainly storage of 
excess energy, although it also provides some protection and insulation of the body. Recently, 
adipose tissue has additionally been recognized as a potent endocrine and paracrine organ 19, 
with its production of hormones such as leptin, adiponectin 19 and cytokines such as tumor 
necrosis factor alpha and interleukin 6 20.  Adiposity, no matter how it is measured, is strongly 
associated with morbidity 21, insulin resistance 5 and  T2DM 22.   
Maternal adiposity is strongly associated with increased risk of GDM 23. Maternal adiposity is 
also associated with several pregnancy related health outcomes for the mother and her 
offspring, such as increased risk of large for gestational age babies 24, foetal death, stillbirth 
and infant death 25 and future obesity in the offspring 26.  
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1.1.1 Fat localization 
Adipose tissue biology depends on its localization. For example, the degree of insulin 
resistance in lean individuals vary with degree of central adiposity 5. Subcutaneous fat is 
generally considered a healthy way of storing fat due to its function as a “metabolic sink” that 
buffers energy excess 27, but subcutaneous fat may lose its ability to store fat in extreme 
energy excess 28. 
Central body fat refers to fat situated in the abdomen, both visceral fat (intra-abdominal) and 
upper body subcutaneous fat (Figure 2).  
  
Figure 2. Illustration of central fat, consisting of both visceral and subcutaneous fat.  
Reprint with permission from the Mayo Foundation for Medical Education and Research. 
 
Visceral fat can be further divided into omental and mesenteric fat, while subcutaneous fat is 
divided into deep and superficial subcutaneous fat 29. Accumulation of deep subcutaneous fat 
is correlated with accumulation of visceral fat 30. Lower body fat is often divided into gluteal 
fat, subcutaneous leg fat and intramuscular fat 29.Central fat is thought to be more 
metabolically active than fat situated elsewhere and is associated with increased risk of 
T2DM 31,32. The role of central fat in pregnancy, however, has been scarcely studied. 
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1.1.2   Measurement of adiposity 
To estimate the amount and distribution of adipose tissue in living humans, several methods 
have been described (Table 1). Underwater weighing, also known as densitometry, was long 
considered the gold standard until technological advances provided computed tomography 
(CT) and magnetic resonance imaging (MRI), which both accurately quantify percent body 
fat, visceral and subcutaneous fat. However, the most accurate methods are expensive, not 
portable and time consuming, making them unsuited for large epidemiological studies. 
Epidemiological studies, with relatively large number of participants, generally demands 
methods that are quick and easy to perform, preferably inexpensive and without large 
measurement error. Hence, in epidemiological studies there is frequent use of surrogate 
measures to estimate the degree of adiposity (Table 1).  
However, not all methods are feasible in pregnancy. Dual x-ray absorptiometry (DXA) and 
CT are not recommended in pregnancy due to ionizing radiation. MRI may be difficult in 
obese, or even in overweight women late in pregnancy, due to the small diameter (usually 60 
cm) of the machine. Waist circumference, as a measure of central adiposity, loses its 
relevance in pregnant women with the growing belly. In addition, several methods are 
challenged by physiological changes natural to pregnancy, such as increased body water due 
to amniotic fluid and increased amounts of extracellular fluid. Underwater weighing usually 
overestimates fat mass in pregnancy, as the extra weight added in pregnancy will have a lower 
density than the lean tissue in non-pregnant 33. The dilution method, on the other hand, 
underestimate fat mass, as the water tracers “escape” into gestational tissues, and leaves a 
falsely low concentration indicating a high proportion of fat-free mass 33. Some correcting 
equations have been made for both methods, but it is generally advised to combine the two if 
high accuracy is demanded. In epidemiological studies of pregnant women, the method 
choices are therefore limited.  
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Table 1. Common methods for assessment of body composition. 
Method Description Strengths and limitations 
Reference methods   
Dissection Dissection of an individual, 
collecting adipose tissue and 
weighing was long considered 
the absolute gold standard 
Obviously accurate, but not 
available in living individuals. 
Underwater weighing 
(Densitometry) 
The individual is weighed both 
in air and underwater. Percent 
body fat is calculated with 
equations based on the principle 
that water has higher density 
than fat 
Was for a long time considered 
the gold standard. Time-
consuming, cannot assess body fat 
distribution, less value in 
pregnancy. 
Air-displacement 
plethysmography 
Uses the same principle as 
underwater weighing, but 
measures air displacement in an 
enclosed chamber. Highly 
reliable and valid as compared 
to underwater weighing 34. 
Much quicker and more 
comfortable than underwater 
weighing. 
Cannot assess body fat 
distribution, scarcely available- 
Dilution method 
(hydrometry) 
Measure total body water using 
isotopes. Based on the 
assumption that the ratio 
between body water and fat-free 
mass is stable. Validated 
equations are used to calculate 
total body water and fat-free 
mass 
Relatively inexpensive, simple 
and safe. The ratio between body 
water and fat-free mass may, 
however, not be stable, especially 
in some situations such as certain 
diseases, weight loss, pregnancy 
etc. 
Dual x-ray absorptiometry 
(DXA) 
Based on two x-ray beams, 
which are absorbed differently 
by bone mineral tissue and soft 
tissue. Fat-free mass, fat mass 
and bone mineral density is 
estimated for arms, legs and 
trunk 
High reproducibility and accuracy. 
Expensive and not portable. Not 
suited in pregnancy due to 
ionizing radiation (although low). 
Computed tomography 
(CT)/magnetic resonance 
imaging (MRI) 
High-resolution images of 
organs and tissues. Highly 
accurate assessment of body 
composition and regional fat 
Considered gold standard. Can 
differentiate between different 
regions of fat. Difficult in 
morbidly obese due to the 
diameter of the machines (usually 
70 cm in CT and 60 cm in MRI), 
can cause a sense of 
claustrophobia (especially MRI). 
Expensive, not portable. CT is not 
suited in pregnancy due to 
ionizing radiation. 
   
Surrogate measures   
Body mass index (BMI) Weight divided by squared 
height. Surrogate for body fat. 
Correlates well with total body fat 
from reference methods at 
population level, poor 
performance at individual level. 
Simple and highly manageable in 
epidemiologic studies. Performs 
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differently across ethnic groups. 
Waist circumference, waist-
to-hip ratio, waist-to-height 
ratio 
Surrogate for central obesity.  Correlates well with central fat 
from reference methods. Simple 
and manageable in epidemiologic 
studies. Problematic in pregnancy, 
as the waist naturally grows. 
Skinfold thickness Skinfold thickness is measured 
with a caliper in certain sites; 
triceps, biceps, subscapular, 
abdomen, suprailiac, thigh. 
Surrogate for body fat and 
regional distribution. Total body 
fat can be calculated based on 
equations 
Correlate well with body fat. 
Simple and manageable in 
epidemiologic studies. Inter-rater 
variability is usually high, 
resulting in low precision. 
Bioelectrical impedance 
analysis (BIA) 
Measures resistance to an 
electrical current that is sent 
though the body to estimate total 
body water. Total body water, 
fat mass and fat-free mass is 
estimated based on in-built 
equations. 
Correlates well with reference 
methods. Relatively inexpensive, 
simple and manageable in 
epidemiologic studies. Is affected 
by body structure, hydration and 
disease status. Some claim that the 
performance may be lower in 
some ethnic groups, as the in-built 
equations are based on large 
sample consisting mainly of 
Western populations.  
   
Biomarkers   
Leptin Reflects body fat. Some 
evidence suggest that free 
(unbound) serum leptin is 
excreted in exact proportions to 
fat mass. Subcutaneous fat is 
thought to correlate better with 
leptin than visceral fat. Large 
adipocytes are thought to 
excrete more leptin than normal 
sized adipocytes.  
Cannot accurately estimate fat 
mass, but is considered a good 
indicator. Simple and manageable 
in epidemiologic studies. Cannot 
assess body fat distribution 
Table adapted from F.B. Hu 35. 
Body mass index 
Body mass index (BMI) is the most widespread surrogate measure of adiposity, and is easily 
calculated based on weight and height (Weight divided by height squared). BMI is widely 
used in epidemiological studies and is considered to provide accurate estimates of body 
composition in adults 36. The World Health Organization (WHO) has developed BMI 
categories based on risk of morbidity (Table 2) 37.  
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In pregnancy, BMI can be used as an indicator of adiposity in a continuous matter, but the 
BMI categories will be more and more misleading as the pregnancy progresses, due to the 
natural weight gain. 
Table 2. Classification of BMI according to the WHO 37. 
Classification BMI cut-offs 
Underweight <18.50 
Normal weight 18.50-24.99 
Overweight 25.00- 29.99 
Obese ≥30.00 
Obese, class I 30.00-34.99 
Obese, class II 35.00-39.99 
Obese, class III ≥40.00 
Skinfolds 
Measurements of skinfold thickness are often used as an indicator of  adiposity and body fat 
distribution 35. Measurements of skinfold thickness are relatively easy to perform in large 
cohorts. Skinfold thickness is measured at predefined sites, usually triceps, biceps, 
subscapular, suprailiac, abdomen and thigh. Although the within observer (intra-rater) 
reliability is usually acceptable, the between observer (inter-rater) variation is usually larger 
38, which may result in imprecision, low reliability and reproducibility. The measurement 
error is generally greater for skinfold thickness measurements than for other anthropometric 
variables 35. Several equations exist to estimate total body fat based on skinfold thickness 35, 
although their estimation performance and validity vary across different populations, e.g. 
ethnic groups. In pregnancy, the measurement of skinfold thickness in the abdominal site 
becomes more difficult as the pregnancy progresses.  
Bioelectrical impedance analysis 
The bioelectrical impedance analysis (BIA) sends electrical currents through the body 
between electrodes, and thereafter measures the resistance (ohm) given by the body before the 
electrical current returns to the other electrode. Based on in-built equations, using age, body 
weight, height and resistance in the body, the BIA scale estimates total body water, muscle 
mass and fat mass. The BIA scales usually measure the resistance via four electrodes at the 
feet that generally measures the resistance in the underpart of the body, or via eight 
electrodes, two for each foot and two for each hand, that measure resistance in the entire body 
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(except from the head). As BIA scales with eight electrodes measure the resistance both in the 
lower and upper part of the body, they are able to estimate central fat mass in addition to total 
fat mass. The estimation of total body water during pregnancy by BIA scales has been found 
valid during pregnancy 39. However, the use of BIA scales for estimation of body fat in 
pregnancy has, as far as I am aware of, not been formally validated. As the variation in body 
water to fat-free mass ratio between individuals increases throughout pregnancy 40, it is 
possible that the estimation of body fat is less accurate in late pregnancy. However, the mean 
body water to fat-free mass ratio is the same throughout pregnancy 40 indicating that on a 
population level, the BIA should perform well. The performance of fat mass in pregnancy 
using BIA has been compared with underwater weighing (known to overestimate fat mass in 
pregnancy) and the dilution method (known to underestimate fat mass in pregnancy). BIA 
correlated with both methods, suggesting that the risk of systematic bias with BIA is low 33. 
Biomarkers 
Adipose tissue secretes several adipokines, which could potentially function as biomarkers of 
fat mass. Both leptin and adiponectin has been associated with GDM, while the evidence for 
association between GDM and other adipokines is sparse 41. Adiponectin is inversely related 
to fat mass, has been associated with insulin-sensitizing effects and is merely considered a 
marker of the metabolic syndrome 42. 
Leptin is a hormone that is secreted by adipose tissue and its discovery was the first evidence 
of major endocrine properties of adipose tissue 19. Leptin is known as the satiety hormone, as 
high concentrations activate leptin receptors in the hypothalamus which inhibits hunger. 
Leptin is also involved in adjustment of energy expenditure. Paradoxically, obese individuals 
have high levels of leptin 43, indicating that the high leptin levels fail to inhibit hunger and to 
increase energy expenditure, possibly due to a reduction in leptin receptors or a general lack 
of leptin’s effect. Serum leptin (s-leptin) is exponentially related to fat mass 44,45, and seems to 
correlate better with subcutaneous fat than with visceral fat in women 46,47. Consistently, 
levels of leptin mRNA are higher in subcutaneous than in visceral adipocytes 48,49, especially 
in women 49. Recently, s-leptin is increasingly being used as an indicator of adiposity. In 
pregnancy, leptin is additionally produced and secreted by the placenta, leading to higher 
levels with progressing pregnancy, followed by a rapid decline to pre-pregnancy levels after 
delivery 50,51. Hence, s-leptin levels will be a better indicator of adiposity in early pregnancy, 
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when the placenta is not yet fully developed, and after delivery when the placenta is no longer 
present.  
1.1.3 Measurement of adiposity and ethnicity 
The use of BMI across ethnicity may represent a challenge, as the relative amount of lean and 
fat tissue may differ across populations. Asians have been found to have a higher amount of 
adipose tissue relative to their BMI than “whites” 52. South Asians have higher levels of leptin 
for the same BMI compared to Europeans 53,54. In accordance with these findings, Asians 
have a considerably higher risk of diabetes at the same BMI level 55,56. Therefore, lower cut-
off levels to define overweight and obesity in certain ethnic groups have been proposed and 
later accepted by the WHO 57,58. However, as proper cut-off levels varies within Asian 
populations, the WHO do not operate with different recommendations, but encourage the use 
of additional cut-offs (Table 3) for reporting purposes 37,58.  
Table 3. Additional cut-offs for BMI according to the WHO 37. 
Classification Principal BMI cut-offs Additional cut-offs1 
Underweight <18.50  
Normal weight 18.50-24.99 18.50-22.99 
  23.00-24.99 
Overweight 25.00- 29.99 25.00- 27.49 
  27.50-29.99 
Obese ≥30.00  
Obese, class I 30.00-34.99 30.00-32.49 
  32.50-34.99 
Obese, class II 35.00-39.99 35.00-37.49 
  37.50-39.99 
Obese, class III ≥40.00  
1 Additional cut-offs for reporting purposes 
 
The validity of BIA scales across ethnic groups is compromised by ethnic differences in how 
well the equations perform. Several studies have derived separate equations for certain ethnic 
groups 59-63, validated against methods that are considered more robust across ethnicity, such 
as DXA. However, the ethnicity specific equations are almost exclusively based on studies 
with small samples, and ethnicity specific equations are not available for all ethnic groups. 
BIA scales have been found to underestimate fat mass in female Asians 59,62,64 and to 
underestimate 59 and overestimate 62 fat mass in black females. 
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Although most methods for body fat assessment across ethnicity are somewhat challenged by 
their dependence on equations based on a certain population, methods such as MRI and CT 
are considered valid across ethnic groups.  Our collaborators in Pune, India, found that 
subscapular and suprailiac skinfolds, as indicators of central deposition of fat, predicted 
glycaemia and insulin resistance while central fat measurements from MRI, DXA or CT did 
not substantially improve the prediction 65, suggesting that skinfolds may be an easy way to 
assess detrimental adiposity in South Asians.  
1.1.4 Maternal adiposity and ethnicity 
The “Adipose tissue overflow” hypothesis—suggesting that South Asians have lower capacity 
to store superficial subcutaneous fat leading to deposition of visceral fat when facing energy 
excess—has been proposed as an explanation for the higher diabetes risk observed in South 
Asians 66. Studies exploring ethnic differences in adiposity are scarce, and the studies mostly 
rely on BMI as a surrogate measure. Among ethnic minorities living in Europe, women from 
the Middle East and Africa seem to have a higher degree of overweight and obesity prior to 
pregnancy, while Asian women tend to have a lower BMI compared to the host population 67.  
1.2 GESTATIONAL WEIGHT GAIN 
Not only pre-existing overweight and obesity, but also excessive gestational weight gain 
during pregnancy may be detrimental to health. The gestational weight gain consists of 
several components; the weight of the foetus, uterus, placenta, mammary glands, intra- and 
extracellular fluid and adipose tissue 68. The individual variation in gestational weight gain is 
mainly thought to be due to differences in fat accretion and total body water. The variation 
between individuals in total body water is higher in the later stages of pregnancy than in early 
pregnancy. 
For the mother, excessive gestational weight gain increases the risk of a number of 
pregnancy-related complications, risk of GDM 68,69 and later obesity and T2DM 68,70. For the 
offspring, excessive gestational weight gain increases the risk of being born large for 
gestational age 71 and obesity in the childhood, adolescence and in adult life 68,72. Moreover, 
some studies suggest that excessive gestational weight gain may increase the cardiovascular 
risk of offspring in adult life, but these findings are inconsistent 72. A too low weight gain in 
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the mother due to nutritional restrictions, on the other hand, seems to increase the risk of the 
offspring to be born small for gestational age 71, and, paradoxically, for obesity, 
cardiovascular disease and T2DM in adulthood 68,72.  
The U.S. Institute of Medicine (IOM) has issued guidelines for what they consider to be 
adequate weight gain during pregnancy (Table 4) 68. These recommendations suggest 
different intervals of weight gain dependent on pre-pregnant BMI, with the aim to reduce the 
risk of adverse consequences for both mother and offspring 70-72. The IOM guidelines have 
been criticized for recommending a too high weight gain, especially for women in obesity 
classes II and III 73. However, the committee members claim that more studies are needed to 
provide obesity class specific guidelines 74. It is important to not recommend a too low 
maternal weight gain, as the evidence is stronger for long-term consequences of maternal 
undernutrition 74. Also, the weight gain recommendations are based solely on observational 
studies, and may therefore not be causally linked with the studied outcomes 68.  
Table 4. Weight gain recommendations during pregnancy across pre-pregnancy BMI category 
according to the U.S. Institute of Medicine 68. 
Pre-pregnant 
BMI 
Total weight gain range 
(kg) 
Rates of weight gain in 2nd and 3rd trimester 
Mean (range) in kg/week 
Underweight 12.5-18.0 0.51 (0.44-0.58) 
Normal weight 11.5-16.0 0.42 (0.35-0.50) 
Overweight 7.0-11.5 0.28 (0.23-0.33) 
Obese 5.0-9.0 0.22 (0.17-0.27) 
First trimester weight gain is estimated to 0.5-2.0 kg 
 
1.2.1 Gestational weight gain and ethnicity 
The U.S. IOM recommendations are not ethnicity specific, despite considerable ethnic 
differences in percent fat mass and disease risk for the same BMI, as outlined previously. 
Studies exploring ethnic differences in gestational weight gain are scarce, and IOM therefore 
encourage research on gestational weight gain across ethnic groups 68. We were only able to 
find two studies from Europe that reported weight gain across ethnic groups 67. One study 
found a statistically lower weight gain in Asians and Africans compared to the Swiss host 
population 75. The other study did not statistically test the ethnic differences in weight gain, 
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but there was a tendency towards a lower weight gain in Sri Lankan and African women 
compared to the Swiss host population 76.  
1.3 HYPERGLYCAEMIA 
The blood glucose concentration needs to be high enough to secure energy to the brain, as it is 
the main fuel that can be utilized by the brain. In addition, the blood glucose needs to stay low 
enough to not damage tissues, as hyperglycaemia is known to cause damage to blood vessels. 
In the normoglycaemic state, insulin is produced and released in relation to the amount of 
glucose in the blood to optimize blood glucose concentration. Insulin works as a signal 
molecule, with several effects on metabolism and growth. The primary function of insulin is 
telling the tissues to transport glucose from the blood stream into the cells, so that the cells 
can either use the glucose as an immediate energy source or store it for later use 77.  
In the fasting state, normoglycaemia is ensured by gluconeogenesis or glycolysis. 
Gluconeogenesis is production of glucose from non-carbohydrate substrates such as pyruvate, 
lactate, glycerol or certain amino acids. Gluconeogenesis is primarily present in the liver, 
although some gluconeogenesis is also present in the kidneys. Glycogenolysis is breakdown 
of glucose stores (glycogen), which mainly appears in the liver. Presence of insulin supresses 
gluconeogenesis and glycogenolysis 77. 
After ingestion of a meal with carbohydrates, absorption of glucose will lead to an increased 
glucose concentration in the blood. In muscle cells, insulin activates glucose transporters 
(GLUT 4) who are translocated to the cell membrane, leading to removal of glucose from the 
blood and into the muscle and adipose tissue. However, tissues do not always respond 
adequately to insulin, and reduction of metabolic effects of insulin is termed insulin 
resistance. Peripheral insulin resistance—when muscle cells, adipocytes or other peripheral 
cells are insulin resistant—mainly results in high postprandial glucose as the muscle cells are 
not able to remove glucose from the blood rapidly enough. Hepatic insulin resistance, on the 
other hand, results primarily in high fasting glucose as neither gluconeogenesis nor 
glycogenolysis is adequately supressed by the presence of insulin. Usually beta-cells 
compensate for elevated insulin resistance by producing extra insulin. When the beta-cells are 
unable to compensate for the increased insulin resistance, it results in hyperglycaemia and 
eventually frank diabetes.  
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Insulin sensitivity is the reciprocal of insulin resistance and the two terms are often used 
interchangeably, although insulin resistance is thought to be the result of both reduced  insulin 
sensitivity and reduced insulin response 78. 
Genetics may play a role in both insulin resistance and beta cell function, although a majority 
of the candidate genes are related to insulin secretion than to insulin resistance79. Insulin 
resistance is strongly associated with adiposity 22, especially central adiposity 5. Visceral fat 
and ectopic fat accumulation in the pancreas have also been proposed as possible mechanisms 
for reduced beta-cell function 80,81.  
1.3.1 Hyperglycaemia in pregnancy 
Pregnancy is accompanied by a number of metabolic and physiological changes to secure 
nutritional flow to the foetus for adequate growth and development 82. Glucose crosses the 
placenta and is the preferred energy source for the foetus. Maternal insulin, on the other hand, 
does not cross the placenta. 
In 12-14 weeks’ gestation, the change in insulin resistance seems to be inversely related to the 
simultaneous accretion of fat mass 83. In the last third, however, insulin sensitivity is 
decreased with 50-60 %, independently of the insulin sensitivity before pregnancy 84-86. 
Despite the high increase in insulin resistance, which otherwise may result in hyperglycaemia, 
the blood glucose levels remain quite stable throughout pregnancy as the foetus utilizes a 
large part 87,88. However, the stable blood glucose levels throughout pregnancy also depend on 
the ability of pancreatic beta cells to compensate by increasing insulin secretion 88,89. 
However, if the beta cells are unable to compensate for the increased insulin resistance, 
hyperglycaemia will ensue.  
Pedersen 90 suggested already in 1952 that maternal hyperglycaemia transmits to the foetus 
and induce foetal hyperinsulinaemia that stimulates foetal growth and thus may lead to 
increased birth weight and excessive body fat in the offspring 90. In accordance with the 
Pedersen hypothesis, maternal hyperglycaemia is associated with  increased foetal insulin 91, 
and with increased birth weight 92-94 and fat mass 95 in the offspring. 
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1.3.2 Gestational diabetes 
GDM is associated with increased risk of later T2DM in the mother 18,96. Maternal type 1 
diabetes, T2DM and GDM have all been associated with increased risk of future obesity and 
T2DM in the offspring 15,97. GDM is associated with high birth weight, cord blood c-peptide 
level, caesarean delivery and neonatal hypoglycaemia 17, as well as metabolic syndrome in 
childhood for the offspring 98. In Europe, the prevalence of GDM varies greatly depending on 
population studied, screening method performed and diagnostic criteria used 99.  
Diagnostic criteria 
O’Sullivan was the first to introduce the screening glucose challenge test to detect GDM 100, 
and O’Sullivan and Mahan  101 were the first to develop pregnancy specific criteria that 
differed from the T2DM criteria used outside pregnancy. The O’Sullivan and Mahan criteria 
were later modified to compensate for advancing laboratory techniques first by the National 
Diabetes Data Group 102 and later by Carpenter and Coustan 103. The Carpenter-Coustan 
criteria have been used extensively since, especially in the U.S.A. The American Diabetes 
Association (ADA) has relied on the  Carpenter-Coustan criteria, but introduced the option of 
performing a 75 g OGTT over 2 hours instead of a 100 g OGTT over 3 hours in 2003 104. The 
criteria based on the O’Sullivan and Mahan criteria are all based on a two-step screening; all 
women undergo a non-fasting 1-hour 50 g glucose load test. If 1-hour glucose levels are 
above 7.8 mmol/l, a 100 g oral glucose tolerance test (OGTT) is performed.  
The WHO operated with the same criteria for GDM as for T2DM up to 1999, when the 2-
hour cut-off value for impaired glucose tolerance (≥ 7.8 mmol/l) was included in the GDM 
criteria 105. The WHO 1999 criteria have since then been used by several Europeans countries, 
including Norway 99.  
The use of several different criteria across countries has reduced the comparability across 
studies and thereby slowing progression of the research. The HAPO study was set up to meet 
the need of international consensus on diagnostic criteria for GDM 106 and was a large 
multicentre cohort of more than 25 000 healthy pregnant women 17. Instead of preventing 
future T2DM risk in the mothers, which was the aim of the O’Sullivan and Mahan criteria101, 
the HAPO study aimed to find thresholds to reduce the frequency of the primary outcomes; 
high birth weight, caesarean section, hypoglycaemia in the newborn and high c-peptide levels 
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in the newborn. The HAPO study found a continuous relationship between maternal glucose 
levels and all primary outcomes 17 suggesting that hyperglycaemia may be detrimental at a 
lower level than previously thought. The International Association of the Diabetes and 
Pregnancy Study Groups (IADPSG)—an umbrella organization to facilitate collaboration 
between research groups with a focus on diabetes in pregnancy—sponsored a workshop in 
2008 gathering 225 researchers from 40 countries to review findings from the HAPO study 
and to discuss GDM criteria, which resulted in a proposition for new GDM criteria 107 (Table 
5). 
Table 5. Overview of different criteria used to diagnose GDM. 
75 g OGTT 
75 or 100g 
OGTT 
100 g OGTT 
 WHO 1999 IADPSG 
2010 
ADA 
2003 
O’Sullivan 
& Mahan 
1964 
National 
Diabetes 
Data 
Group 
1979 
Carpenter 
& 
Coustan 
1982 
Screening 
method 
At risk individuals  One-step 
universal 
screening 
Two-step 
universal 
screening 
Two-step 
universal 
screening 
Two-step 
universal 
screening 
Two-step 
universal 
screening 
 Venous plasma 
(mmol/l) 
Venous plasma 
(mmol/l) 
Venous 
plasma 
(mmol/l) 
Venous 
whole blood 
(mmol/l) 
Venous 
plasma 
(mmol/l) 
Venous 
plasma 
(mmol/l) 
Fasting ≥ 7.0 ≥ 5.1 ≥ 5.3 ≥ 5.0 ≥ 5.8 ≥ 5.3 
1 h  ≥ 10.0 ≥ 10.0 ≥ 9.1 ≥ 10.6 ≥ 10.0 
2 h ≥ 7.8 ≥ 8.5 ≥ 8.6 ≥ 8.0 ≥ 9.2 ≥ 8.6 
3 h   ≥ 7.8 ≥ 6.9 ≥ 8.1 ≥ 7.8 
Abnormal 
values 
needed 
1 1 2 2 2 2 
Additional 
comments 
 
Adopted by ADA 
2012 and  
WHO 2013 
3 h cut-off 
only 
applies if 
100 g 
OGTT is 
performed 
   
OGTT = Oral glucose tolerance test; h = hour; WHO = World Health Organization; IADPSG = International 
Association of Diabetes and Pregnancy Study Groups; ADA = American Diabetes Association. Table adapted 
from Buckley et al. 99. 
 
If the GDM criteria developed by the IADPSG 107 are used, the prevalence tends to increase 
compared to formerly used criteria, leading to concerns regarding labelling a large fraction of 
pregnant women as ill 108. The IADPSG criteria were adopted by the ADA in 2011—although 
ADA reintroduced the Carpenter and Coustan based criteria in 2014 due to lack of evidence 
109—and by the WHO in 2013 110. However, the WHO does not explicitly recommend 
universal screening, and do not demand collection of 1-hour glucose values. 
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1.3.3 Gestational diabetes and ethnicity 
Studies from Europe find a higher risk of GDM in several ethnic minorities with non-western 
origin compared to the host populations 67. South Asians unambiguously have a higher risk of 
GDM, while the GDM risk seem to vary within other ethnic groups in studies from Europe 67. 
The prevalence of GDM in the STORK Groruddalen study by the WHO 2013 criteria (based 
on fasting and 2-hour glucose, 1-hour glucose not available) was 31.5 %, whereof 24.0 % 
among Western Europeans and 36.8 % among non-western ethnic minority women 111. South 
Asians had the highest prevalence, with a 1.8 fold higher risk of GDM compared to Western 
Europeans 111. South Asians have been found to have high degree of insulin resistance, which 
is thought to contribute greatly to their higher diabetes risk 112. Findings from the U.S.A. 
indicate that some ethnic groups may have a higher risk of recurrence of GDM in subsequent 
pregnancies than “non-Hispanic White” 113, while ethnic differences in recurrence rates of 
GDM in Europe does not seem to have been studied. 
1.4 DYSLIPIDAEMIA 
Dyslipidaemia refers to abnormal amounts or composition of blood lipids, such as cholesterol 
and fatty acids. High serum levels of triglycerides and low density lipoprotein (LDL)-
cholesterol and low levels of serum high density lipoprotein (HDL)-cholesterol have been 
associated with insulin resistance, the metabolic syndrome, atherosclerosis and increased risk 
of cardiovascular disease 114-116. Lately, excess energy and high circulating lipid levels have 
been associated with accumulation of ectopic fat, which in turn is associated with reduced 
function of the affected organ and metabolic disturbances  117.  
Insulin resistance is closely associated with dyslipidaemia 22,118, especially 
hypertriglyceridaemia, as insulin resistance leads to increased flux of non-esterified fatty 
acids (NEFA) which results in increased production and decreased clearance of  the 
triglyceride-rich very-low density lipoprotein (VLDL) particles 119. Low HDL-cholesterol and 
small dense LDL-cholesterol are also highly associated with insulin resistance and T2DM, 
although the exact mechanisms are not well understood 119. There are some indications that 
dyslipidaemia could be a causal factor for insulin resistance 120.  Obesity, and especially 
central obesity, is also highly associated with dyslipidaemia, although this relationship could 
be mediated by insulin resistance 27.  
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1.4.1 Dyslipidaemia in pregnancy 
The concentration of maternal serum lipids changes during the normal pregnancy, probably 
mostly due to increased insulin resistance and hormonal changes 88. Although the placental 
transfer of most lipids is low, except for essential fatty acids and cholesterol, lipids play an 
important role in indirect provision of nutritional fuels to the foetus, such as ketone bodies 
which pass the placenta 87.  
In early pregnancy, maternal body fat accumulation is increased, while during the last third of 
pregnancy there is a breakdown of maternal fat depots 87. The increased insulin resistance, in 
combination with several other changes in pregnancy, contribute to the increased lipolytic 
activity in maternal fat depots. The breakdown of maternal fat depots results in the release of 
NEFAs and glycerol which are transported to the liver. In the liver, glycerol may be used as a 
substrate for gluconeogenesis, and NEFA for synthesis of ketone bodies, or to form VLDL-
cholesterol to transport triglycerides to peripheral tissue for energy production or energy 
storage 77,87. In late pregnancy, the activity of lipoprotein lipase is reduced due to the 
increased insulin resistance 88, resulting in hypertriglyceridemia as the VLDL is not as 
effectively removed from the blood 87,88.  
In women with GDM, the dyslipidaemia is further exacerbated as they often start their 
pregnancy with a higher degree of insulin resistance compared to healthy pregnant women. 
Women with GDM have elevated serum triglycerides 121. Studies have found associations 
between maternal lipids during pregnancy and foetal growth, especially maternal triglycerides 
and HDL-cholesterol 122-127. One study recently found that total cholesterol was of similar 
importance as maternal glucose for predicting birth weight 128. These results may indicate that 
increased maternal lipid levels provide the foetus with increased amounts of energy. 
1.4.2 Maternal dyslipidaemia and ethnicity 
Ethnic differences in maternal serum lipids are scarcely reported. In the Amsterdam Born 
Children and their Development study, lipid levels varied across ethnic minority groups, with 
the most detrimental lipid profile in Surinam-Hindustani and Turkish women 129. However, 
the adverse lipid profiles were largely explained by BMI 129. Another study in pregnant 
women found that Asian Indians had lower HDL-cholesterol and higher serum triglycerides 
compared to ethnic European women 130. These findings in pregnant women are supported by 
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results from non-pregnant, showing that South Asians have low HDL cholesterol and high 
triglycerides 131,132; Turkish women have high levels of serum triglycerides 133, while black 
Caribbean and black African seem to have more favourable lipid profiles 134.  
1.5 MECHANISMS LINKING 
ADIPOSITY,HYPERGLYCAEMIA AND 
DYSLIPIDAEMIA 
Adiposity, especially central adiposity, is strongly associated with insulin resistance and 
dyslipidaemia. The association between central adiposity and metabolic disturbances is not 
necessarily causal, but could simply be a result of being coincidentally associated with the 
same causal factor 135. There are, however, indications of reversibility, with reduction of 
visceral fat causing greater insulin sensitivity or improved beta cell function, suggesting a 
possible causal role of central adiposity. Lim and co-workers 136 showed that 8 weeks on a 
very low calorie diet resulted in weight loss, decreased pancreatic and hepatic triglyceride 
content, and improved insulin sensitivity and beta cell function, resulting in normalization of 
fasting glucose and HbA1c levels. Conversely, eight weeks of overfeeding led to weight gain, 
decreased insulin sensitivity and increased  levels of intrahepatic lipids 137. Barzilai and co-
workers 138 found a marked improvement of insulin sensitivity and reduction in hepatic 
glucose production after visceral fat was removed surgically, although this experiment was 
performed in rats and thereby not necessarily transferable to humans. Further support of the 
importance of fat localisation in relation to diabetes risk is the finding that insulin sensitizing 
agents such as pioglitazone, which lead to a shift in body composition from central fat 
distribution to more peripheral fat storage even though the total fat mass is often increased, 
has shown to reduce insulin resistance 139.  
Dyslipidaemia has also been proposed as a causal factor for insulin resistance, as high 
circulating lipid levels are thought to cause ectopic lipid accumulation 117. A mendelian 
randomization study did not find any effect of genetically raised triglyceride levels on risk of 
T2DM 140. Also, LDL-cholesterol has been excluded as a potential causal factor for insulin 
resistance 120. However, there are studies indicating that lipoprotein lipase function may be 
important in impaired insulin sensitivity 120. 
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There is increasing consensus that ectopic fat accumulation  in muscle and liver is important 
in the development of insulin resistance in humans 117. Evidence is also emerging, indicating 
that ectopic fat accumulation in the pancreas may be responsible, at least partially, for the beta 
cell dysfunction seen in diabetes 80,81.  In concordance with these findings are also the 
previously mentioned findings that substantial weight loss led to decreased pancreatic and 
hepatic fat, normalized beta cell function and reversal of T2DM 136. Another study showed 
that lipid content in the pancreas was higher in T2DM cases than in controls 80.  
1.6 DEVELOPMENTAL ORIGINS OF HEALTH AND 
DISEASE 
The Developmental Origins of Health and Disease (DOHaD) concept represents the idea that 
poor conditions in early life increase the risk of non-communicable disease in adult life, such 
as cardiovascular disease, T2DM, obesity and other metabolic disorders 141. Anders Forsdahl 
142 found that cohorts born in years with high infant mortality was succeeded by higher 
mortality from cardiovascular risk 40-60 years later than cohorts born in years with lower 
infant mortality, and concluded that poor living conditions in early life followed by 
abundance could be a risk factor for cardiovascular events 142. Hales and Barker with co-
workers proposed their theory of the thrifty phenotype in the 1990s, suggesting that foetuses 
exposed to undernutrition are programmed in utero to cope with harsh living conditions in 
later life. They found that low birth weight was highly associated with several diseases in 
adulthood, including T2DM 143,144. Although Hales’ and Barker’s hypothesis that low birth 
weight increased risk of T2DM led to controversy when they presented it, their hypothesis 
was later supported by studies in twins, showing that birth weight was lower in twins who 
developed T2DM in adulthood compared to their non-diabetic mono-zygotic twin 145. The 
detrimental effects of being born small for gestational age are now well established.  
The DOHaD concept is largely based on the ideas of Hales and Barker, and was further 
supported by findings from the Dutch Hunger Winter study 146. The Dutch Hunger Winter 
study showed that maternal undernutrition during pregnancy affected offspring’s adult health 
independently of social class and other potential confounding factors, and that the timing of 
undernutrition was important 147. 
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1.6.1 The developmental overnutrition hypothesis 
Historically, there has been a major focus on the relationship between maternal 
undernutrition, low birth weight and chronic disease in adult life. However, during the last 
decades, with the evolving obesity epidemic, concerns about maternal overnutrition have 
emerged. The developmental overnutrition hypothesis suggests that overnutrition in utero—
driven by obesity, excessive weight gain or diabetes in the mother— lead to permanent 
metabolic changes in the foetus which, in turn, will increase the risk of adiposity and diabetes 
in later life 91. However, whether these associations are due to in utero programming of the 
foetus or shared genes and lifestyle between the mother and her offspring, are debated. 
Although shared genes and lifestyle are thought to play a major part in the risk of offspring 
adiposity, studies in siblings suggest a strong intra uterine effect of diabetes. A study that 
explored the effect of maternal diabetes and BMI in siblings born before and after onset of 
diabetes in the mother, showed that intrauterine exposure to maternal diabetes substantially 
increased the offspring’s BMI (BMI was 2.6 (95 % confidence interval (CI) 0.9-4.3) kg/m2 
higher in exposed siblings) and the risk of T2DM (odds ratio (OR) (95 % CI) 3.7 (1.3-11.3) 
for exposed siblings)16. However, they found no differential risk in siblings born before or 
after onset of diabetes in their father 16. A study of female Pima Indians with a mutation 
resulting in maturity-onset diabetes of the young showed that diabetes developed 12 years 
earlier in offspring of whose mothers had already developed diabetes prior to pregnancy 
compared to offspring whose mothers had not yet developed diabetes (P<0.0001) 14. They 
found no difference in age at diagnosis when the father was diagnosed at a young age 14. 
Similarly, a study in siblings found that excessive gestational weight gain during pregnancy 
contributed to later offspring obesity in overweight and obese, but not in normal weight 
mothers 148. However, a large part of the associations between gestational weight gain and 
later offspring BMI were explained by shared familial characteristics. In relation to pre-
existing obesity, a study that followed siblings born before or after large weight loss after 
obesity surgery found that maternal surgery substantially reduced the prevalence of obesity in 
the 2-18 year old offspring 149. 
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1.7 NEONATAL ANTHROPOMETRY 
Big babies are associated with increased risk of complications such as caesarean section, 
shoulder dystocia, asphyxia and neonatal hypoglycaemia 150. High birth weight has been 
associated with long-term risk for childhood and adult overweight and obesity 151,152, as well 
as T2DM in later life 153. Gestational weight gain seems to play an independent role in the 
development of high birth weight and adiposity in the neonates 68.  
Although easy to measure, birth weight is generally considered a rough indicator of foetal 
growth, as the differences in birth weight may be attributed both to differences in fat and lean 
mass 154. Hence, neonatal fat mass is considered a more sensitive marker of the foetal 
environment and a more specific outcome measure of foetal growth than birth weight 155,156. 
Although neonatal fat mass has been suggested as an early indicator of childhood obesity, the 
long-term health impact of neonatal fat mass seems to be scarcely studied. 
1.7.1 Neonatal anthropometry and ethnicity 
The optimal birth weight may differ across different populations, and studies find distinct 
differences in birth weight across ethnic groups, with offspring of women originating from 
low income countries having lower birth weight than European host populations 67. Offspring 
of Africans tend to have a relatively high birth weight, while offspring of South Asians tend 
to have a low birth weight compared to offspring of Europeans 67. However, despite lower 
birth weight, babies born in India seem to preserve their subcutaneous fat mass compared to 
babies born in England, referred to as the thin-fat phenotype 157.  
In the STORK Groruddalen Study, offspring of women from Pakistan, Sri Lanka/India or 
East Asia had lower birth weight than Western Europeans 158, while there were no difference 
between Western Europeans and offspring of women from the Middle East, sub-Saharan 
Africa or Eastern Europe. However, among the offspring with low birth weights, Pakistani 
offspring were the only group who had less subcutaneous fat than Western Europeans, while 
Sri Lankans/Indians and East Asians had similar amounts of subcutaneous fat 158. 
Subcutaneous fat in the newborn may be a better indicator of the foetal environment than 
birth weight in a multi-ethnic population, and possibly a better predictor for future health of 
the offspring. 
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2 AIMS 
  
The overall aims of this thesis were to increase the understanding of how maternal adiposity 
is related to GDM, and how maternal adiposity, hyperglycaemia and dyslipidaemia influence 
the newborn offspring’s birth weight and amount of subcutaneous fat. 
The specific objectives were to: 
- explore the effect of mid-gestational weight gain and gain of total fat, central fat and 
subcutaneous fat on the risk of GDM (Paper 1) 
- explore differences between Europeans and South Asians in BMI, subcutaneous fat and 
s-leptin levels during and after pregnancy (Paper 2) 
- explore the effect of BMI, subcutaneous fat and s-leptin levels in early pregnancy on 
the risk of GDM (Paper 2) 
- explore whether the effects of maternal glucose and lipid levels on offspring’s birth 
weight and subcutaneous fat were independent of early pregnancy BMI and mid-
gestational weight gain (Paper 3) 
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3 METHODS 
3.1 STUDY DESIGN AND SUBJECTS 
The methods of the STORK Groruddalen study have been described in detail previously 159-
161. The STORK Groruddalen study is a prospective cohort study of pregnant women living in 
Groruddalen, a multi-ethnic area of Oslo. Inclusion was conducted during 2008-2010. 
Groruddalen cover affluent as well as more deprived residential areas. A local information 
campaign was set up prior to the recruitment of pregnant women, and all general practitioners 
in the study area were asked to refer pregnant women as early as possible to the child health 
clinics. Women were recruited by midwives in early pregnancy at three child health clinics, 
covering three out of the four districts in Groruddalen. Women were eligible if they: 1) lived 
in the study districts; 2) planned to give birth at one of two study hospitals; 3) were in < 20 
week’s gestation; 4) could communicate in Norwegian or any of the eight translated 
languages; 5) were able to give an informed consent. Women with pre-existing diabetes or in 
need of intensive hospital follow-up during pregnancy were excluded.  
To facilitate the inclusion of Pakistani and Somali women, the inclusion criteria was slightly 
changed 6 months after study start to allow for inclusion of these groups if < 25 weeks’ 
gestation 161.  
The attendance of the STORK Groruddalen cohort is presented in Figure 3 and has been 
described in detail elsewhere 159. The participation rate was 74 % (Figure 3), and varied from 
82 % in Europeans, 71 % in Asians, 65 in Middle Easterners to 64 % in Africans 159. Age did 
not differ between the 823 who participated and the 291 who chose not to participate 159. 
South Asians who did not participate were more parous than those who participated, while the 
rates for parity were similar within the remaining ethnic groups 159. The study cohort was 
found to be fairly representative for the main ethnic groups 111, and there were no ethnic 
differences in reasons for exclusion 111,159. 
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Figure 3. Attendance in the STORK Groruddalen cohort.  
Reprint from Jenum et al. 2010 159 with permission from SAGE Publications. 
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The flow of the cohort is described in Papers 1-3 and in Figure 4.  
 
 
Figure 4. Study samples for papers 1-3.  
V2—Visit 2, OGTT—Oral glucose tolerance test, BIA—bioelectrical impedance analysis. 
3.2 ETHICS 
The study was approved by the Regional Ethics Committee. Written consents were obtained 
from each woman on behalf of herself and her offspring. The storage of biological material 
was approved by the Regional Ethics Committee and the Norwegian Directorate of Health. 
Data was stored in agreement with the standards of the Norwegian Data Inspectorate and 
handled anonymously. The study was conducted in agreement with the Helsinki declaration. 
  
Paper 1
Weight gain, regional fat gain and 
GDM
Paper 3
Effect of maternal glucose, lipids and weight 
on offspring’s birth weight and skinfolds
Paper 2
Maternal adiposity in South 
Asians vs. Europeans and GDM
Included (n = 823)
73.9 % of the invited
42.9 % of all
Attended V2 
(n = 772)
Underwent OGTT
(n = 759)
Study sample paper 2
(n = 728)
Singleton live neonates
(n = 751)
Study sample paper 3 outcome 
birth weight
(n = 699)
Study sample paper 3 
outcome sum of skinfolds at birth
(n = 512)
Europeans (n = 379) and South 
Asians (n = 200)
Europeans (n = 356) and South 
Asians (n = 191) 
with OGTT
Study sample paper 1
for association with GDM
Europeans (n = 353) and South 
Asians (n = 190) 
with s-leptin at V1
Excluded
7 missing values at 
V2, 13 lacked BIA, 1 
computation of 
wrong height in BIA, 
10 with South or 
Central American 
origin
Excluded
37 preterm, 6 
mothers included 
late in pregnancy, 
9 with South or 
Central American 
origin
Study sample paper 1
for changes during pregnancy 
and retention
Europeans (n = 309) and South 
Asians (n = 158) 
who met at 14 weeks after 
delivery
8 twin pairs, 6 
stillbirths, 7 lost to 
follow-up
15 abortions or stillbirths < 28 weeks, 
6 complications for mother or baby, 
30 lost to follow-up
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3.3 DATA COLLECTION 
Women were included at (mean ± standard deviation (SD)) 15 ± 3 weeks’ gestation (Visit 1), 
re-examined at 28 ± 1 weeks’ gestation (Visit 2) and 14 ± 3 weeks after delivery (Visit 3) 
(Table 6). All information material and questionnaires were translated to Arabic, English, 
Sorani, Somali, Tamil, Turkish, Urdu and Vietnamese and quality controlled by bilingual 
health professionals. Professional interpreters were used when necessary (for 22 % of the 
women 161). 
 
Table 6. Overview of collected data used in this thesis. 
 Pre-
pregnancy  
Visit 1 
(week <20) 
Visit 2 
(week 21-29) 
Delivery 
(0-72 hours 
after delivery) 
Visit 3 
(10-14 weeks 
after delivery) 
Used in 
Paper 
Maternal       
Ethnicity, age, parity, 
family history of 
diabetes 1, smoking 2 
 X    1, 2, 3 
Height  X    1, 2, 3 
Weight Self-reported 
at Visit 1 
X X  X 1, 2, 3 
Bioelectrical 
impedance analysis 
 X X  X 1 
Skinfolds  X X  X 1, 2 
Biological markers  X X  X  
   Fasting glucose  X3 X3,4  X3 1, 2, 3 
   2-hour glucose   X3,4   1, 2, 3 
   C-peptide  X X  X 1, 2 
   Leptin  X X  X 2 
   Insulin  X X  X 2 
   HbA1c  X X  X 2 
   Total cholesterol  X X  X 3 
   HDL-cholesterol  X X  X 3 
   LDL-cholesterol  X X  X 3 
   Triglycerides  X X  X 3 
       
Neonatal       
Gestational age 5      3 
Weight    X  3 
Skinfolds    X  3 
Sex    X  3 
1 Used only in paper 2. 
2 Used only in paper 3 
3 Glucose measured in serum (Vitros). 
4 Glucose measured in full blood on site (Hemocue)  
5 Based on mothers last menstrual period unless large variation from age estimated with routine 
ultrasound at 17-20 weeks’ gestation. 
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3.3.1 Ethnicity 
In this thesis, ethnicity was defined as country of birth or participant’s mother’s country of 
birth if the participant’s mother was born outside of Europe or North America, in 
correspondence with suggestions from Senior and Bhopal 162. In the three papers of this 
thesis, the terms ethnicity, ethnic origin etc. are used inter-changeably, but all refer to the 
above definition. 
The STORK Groruddalen study comprises women born in 65 different countries. To assure 
statistical power, countries of birth were merged into ethnic groups, while trying to retain 
certain homogeneity in the groups (Table 7). Three women from North America (whereof two 
had ethnic Norwegian ancestry) were categorized into the ethnic group “Europe”, as they 
were considered to be quite homogenous. Somalia was categorized together with 5 women 
from other countries of the Horn of Africa, 12 women from other Sub-Saharan countries and 
with 5 women from Nigeria into the ethnic group “South and Central Africa”.  
Table 7. Overview of the classification of ethnic groups used in this thesis. 
  
Europe South 
Asia 
East 
Asia 
Middle 
East 
South and 
Central 
Africa 
Excluded Total 
Norway 313  
Eastern Europe 43  
Other Scandinavia 13  
Other Western European countries 7  
North America 3  
Pakistan 126  
Sri Lanka 61  
Other South Asian countries 13  
Vietnam 18  
The Philippines 13  
Other East Asian countries 13  
Iraq 38  
Turkey 28  
Morocco 27  
Afghanistan 13  
Other Near or Greater Middle Eastern countries 20  
Somalia 40  
Other African countries South of Sahara 22  
South or Central America           12  
  379 200 44 126 62 12 823 
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Only 52 women (6.3 %) were second generation immigrants from outside Europe or North 
America, and thereby classified into their mother’s country of birth. The majority of these 
originated from Pakistan (n = 40). 
In papers 1 and 3 all ethnic groups, except women from South or Central America, were 
included, while in paper 2, only Europeans and South Asians were included, (Table 7). In all 
three papers, we excluded women from South or Central America due to low numbers and 
heterogeneity of ethnic origin. 
3.3.2 Questionnaire data 
Questionnaire data used in this thesis were collected at Visit 1. All questionnaires were 
interviewer-administered by midwives and study personnel. Parity was defined as previous 
viable pregnancies and used as a dichotomized variable; parous or nulliparous. Maternal age 
was calculated from participant’s date of birth. Weeks’ gestation was based on first day of the 
last menstrual period. Due to low numbers of smokers in the cohort, we merged two questions 
regarding smoking; 1) smoked within three months prior to conception, and 2) smoked during 
pregnancy, and dichotomized into non-smokers versus occasional or regular smokers. The 
women were asked about their pre-pregnancy body weight shortly after being weighed at 
Visit 1.  
3.3.3 Maternal anthropometrics 
Maternal height was measured at visit 1 by a fixed stadiometer, calibrated before study start 
and thereafter biannually. Pre-pregnancy body weight was self-reported at visit 1 and weight 
was measured at Visit 1, Visit 2 and Visit 3, to the nearest 0.1 kg by a digital scale, calibrated 
before study start and thereafter biannually (Tanita-BC 418 MA, Tanita Corporation, Tokyo, 
Japan). BMI was calculated as the weight in kg divided by the height in meters squared.  
Total body fat and central fat (referred to as truncal fat in paper 1) was measured at Visit 1, 
and Visit 2, with a BIA scale (Tanita-BC 418 MA). The use of Tanita-BC 418 MA has been 
validated in humans 163 and is not thought to result in systematic bias when estimating fat 
mass in pregnancy 33. As the accuracy varies across ethnic groups, as previously discussed, 
we used the intra-individual change to avoid potential bias across ethnic groups. 
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Skinfolds were measured twice at Visit 1, Visit 2 and Visit 3, to the nearest 1 mm with a 
caliper (Holtain T/W Skinfold Caliper, Holtain Ltd., Crymych, UK). The mean value of the 
two measurements was subsequently used. The skinfolds were measured at the triceps, 
subscapular and suprailiac sites. In paper 1, we used the mean of all three skinfold sites as a 
variable. In paper 2, we summarized all three sites, and used sum of skinfolds as a variable. 
Five raters measured maternal skinfolds after receiving extensive training. Inter-rater 
variability, expressed as % Technical Error of Measurement (%TEM) 38 was assessed twice a 
year. Inter-rater variability ranged from 5 to 21 % between study personnel. Intra-rater 
variability was less than 5 % for all measurements 158.  
We used the measured weight gain between Visit 1 and Visit 2 divided by number of weeks 
between the two measurements to explore mid-gestational weight gain. We used IOMs 
recommended range of weight gain per week in second and third trimester for specific BMI 
categories 68 to classify women into having  inadequate, adequate or excessive weight gain. 
3.3.4 Laboratory methods 
Fasting venous samples with serum were collected at Visit 1, Visit 2 and Visit 3. The samples 
were put on ice and daily shipped to the laboratory at the Department of Multidisciplinary 
Laboratory Medicine and Medical Biochemistry, Akershus University Hospital. Fasting 
glucose, total cholesterol, HDL-cholesterol, LDL-cholesterol and triglycerides were measured 
using a colorimetric method (Vitros 5.1 FS, Ortho Clinical Diagnostics) 111,164. Fasting C-
peptide and insulin were measured at the Hormone Laboratory, Oslo University Hospital, by 
non-competitive immunofluorometric assays (DELFIA, PerkinElmer Life Sciences, Wallac 
Oy, Turku, Finland). Homeostasis model assessment of insulin resistance (HOMA-IR) was 
estimated by the Oxford University HOMA Calculator 2.2 using C-peptide. HbA1c was 
analyzed in full blood with HPLC (Tosoh G8). Fasting venous samples of serum was 
biobanked and stored at -80°C prior to analysis of leptin levels. S-leptin levels were analysed 
by HADCYMAG-61K based on the Luminex® xMAP® technology (Milliplex® Map, 
Millipore Corporation, Billerica, MA, U.S.A.) at the Hormone Laboratory, Oslo University 
Hospital, Oslo.  
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At Visit 2, fasting and 2-hour glucose after a 75 g OGTT, were analysed both by using a 
patient near “Point of Care“ method (HemoCue, Angelholm, Sweden) and by using the 
previously described method (Vitros).   
Women were diagnosed with GDM at Visit 2 according to the WHO 1999 criteria (fasting 
glucose ≥ 7.0 mmol/l or 2-hour glucose ≥ 7.8 mmol/l). Women diagnosed with GDM by the 
WHO 1999 criteria received lifestyle advice and were referred to their General Practitioner 
for follow-up if 2-hour glucose was <9.0 mmol/l or to hospital care if 2-hour glucose was ≥ 
9.0 mmol/l 111. 
In this thesis, GDM was defined by the WHO 2013 criteria (fasting glucose ≥ 5.1 mmol/l and 
2-hour glucose ≥ 8.5 mmol/l) at Visit 2, due to the emergence of new criteria.  
3.3.5 Neonatal characteristics 
Gestational age was calculated from the first day of the woman’s last menstrual period (LMP) 
and term was calculated as date of LMP +282 days. If the LMP date was missing or differed ≥ 
14 days from the term estimated by routine ultrasound in week 17-20, we used the ultrasound 
term (n= 24 (3.4%)) 158. The outcome birth weight was measured with electronic scales 
immediately after birth 159.  
Neonatal skinfolds at subscapular, suprailiac, thigh and triceps sites were measured twice, to 
the nearest 0.2 mm, with a skinfold caliper (Holtain T/W Skinfold Caliper, Holtain Ltd., 
Crymych, UK) within 72 hours after birth. The mean value of the two measurements was 
subsequently used.  
The sum of skinfolds was calculated by summarizing the four skinfold sites. Two raters 
measured neonatal skinfolds after receiving extensive training. Inter-rater variability 
(measured as % Technical Error of Measurement) for the skinfold measurements ranged from 
8-13%,  while the intra-rater variability varied from 2.9 % in the thigh skinfold to 4.3 % in the 
suprailiac skinfold 158.  
  
33 
 
3.4 STATISTICS 
All statistical analyses were performed by me, using IBM SPSS statistics 19-22 (Chicago, IL, 
USA). Data are presented as mean and SD if normally distributed, median and inter-quartile 
range if non-normally distributed and number and percent if categorical. Effect estimates were 
presented with 95 % confidence intervals. P < 0.05 was considered statistically significant. 
Non-normally distributed variables were transformed as appropriate to attain normal 
distribution prior to performing parametric statistical tests. We performed logistic regression 
analyses in papers 1 and 2, multivariate general linear models in paper 2 and linear regression 
in paper 3. In papers 1 and 3, we used the lincom command in StataIC 12 (StataCorp LP, 
College station, TX, USA) to calculate sole and combined risks based on the respective 
regression model. 
To explore potential bias in the-self-reported pre-pregnancy weight, we used general linear 
models to explore differences between self-reported pre-pregnancy weight and measured 
weight at Visit 1, across BMI and ethnicity. In paper 3, we used analysis of variance to 
explore interference between quartiles of triglyceride levels and glucose measured with 
HemoCue to decide on whether to use glucose variables measured with Vitros or HemoCue in 
the paper. 
3.4.1 Standardization of explanatory variables 
In paper 2 and 3, we standardized the explanatory variables in order to easier compare their 
effect on the outcome against each other. The Z-score standardize continuous variables that 
are normally distributed by giving every observation a standardized value based on its number 
of SDs from the sample mean (Individual observation – sample mean  / sample SD). E.g. if a 
participant has a BMI of 40, the sample mean BMI is 25.3 and the SD is 4.9, the participant’s 
z-score will be (40-25.3) / 4.9 = 3, giving a standardized BMI of 3 SDs above the mean.  
3.4.2 Adjustments for covariates 
In all three papers, we adjusted for selected covariates that differed across the ethnic groups. 
Weeks’ gestation at inclusion was adjusted for in all analyses, as it varied slightly between 
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ethnic groups. Age and parity were adjusted for in all analyses as they varied across ethnic 
groups, and as they have been associated with both gestational weight gain 68 and GDM 165.  
3.4.3 Interactions 
When exploring relationships across groups it is important to check whether the risk factors 
relate to the outcome similarly in the different groups. Relationships between risk factors and 
outcomes may vary across ethnic groups and relationships may differ when certain variables 
are taken into account. In all three papers we explored interactions between ethnicity and the 
explanatory variables. 
3.4.4 Statistical power considerations 
Power calculations were performed prior to study start to secure a large enough sample size to 
detect ethnic differences in the prevalence of GDM defined by the WHO 1999 criteria 159. The 
expected prevalence of GDM was 5 % in Western women, 20 % in South Asians and 10 % in 
the remaining ethnic groups. Based on the ethnic composition attending the three child health 
clinics, the needed number of GDM cases was estimated to 100 women, and the sample size 
needed was estimated to 800 women 159. The shift in GDM criteria during the study period 
resulted in more GDM cases than expected (99 according to the WHO 1999 criteria and 239 
according to the WHO 2013 criteria) and thereby improved statistical power. Pre-study power 
calculations specific to this thesis were not performed, although we tried to preserve the 
statistical power by using continuous explanatory variables when appropriate. The statistical 
power was satisfactory for the three papers included in this thesis, especially for differences 
between the three largest ethnic groups. 
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4 RESULTS 
4.1 PAPER I 
Weight gain, total fat gain and regional fat gain during pregnancy and the association 
with gestational diabetes: a population-based cohort study. 
In paper 1 we investigated the association between mid-gestational weight gain and gain of 
total fat, central fat and subcutaneous fat and GDM as defined by the WHO 2013 criteria.  
We found that mean mid-gestational weight gain in our cohort was in the upper part of the 
intervals recommended by the IOM guidelines for weight gain during pregnancy. We did not 
find significant ethnic differences in weight gain, although differences in some of the other 
indicators of adiposity were observed. Women from Africa had significantly lower gain of 
total fat mass, central fat mass and mean skinfold thickness than Europeans, while East 
Asians had a higher gain of mean skinfolds than Europeans. 
Mid-gestational weight gain and gain of total fat, subcutaneous fat and especially central fat 
were associated with increased risk of developing GDM. 
4.2 PAPER II  
Ethnic Differences in BMI, Subcutaneous Fat and Serum Leptin Levels During and 
After Pregnancy and Risk of Gestational Diabetes. 
In paper 2 we explored differences between European and South Asian women in early 
pregnancy BMI, subcutaneous fat and s-leptin during and after pregnancy and their 
relationship with GDM as defined by the WHO 2013 criteria. 
We found that South Asians had similar amounts of subcutaneous fat and higher s-leptin in 
early pregnancy (14 weeks’ gestation) than Europeans, despite a lower BMI. South Asians, in 
comparison to Europeans, retained more weight and subcutaneous fat 14 weeks after delivery. 
Mean s-leptin levels decreased more in Europeans than in South Asians between 14 weeks’ 
gestation and 14 weeks after delivery. At the examination 14 weeks after delivery, South 
Asians had more subcutaneous fat and higher levels of s-leptin than Europeans, and there 
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were no longer any difference in BMI between South Asians and Europeans. In early 
pregnancy (14 weeks’ gestation) parous South Asians had more subcutaneous fat and s-leptin 
than parous Europeans, while we found no such ethnic difference in nulliparous. BMI, 
subcutaneous fat and s-leptin were all risk factors for GDM.  
The higher weight and fat retention in South Asians may leave South Asians at a higher risk 
of GDM in future pregnancies. 
4.3 PAPER III 
Effects of early pregnancy BMI, mid-gestational weight gain, glucose and lipid levels in 
pregnancy on offspring's birth weight and subcutaneous fat. A population-based cohort 
study. 
In paper 3 we explored whether the effects of maternal glucose and lipid levels on offspring’s 
birth weight and neonatal subcutaneous fat were independent of early pregnancy BMI and 
gestational weight gain. 
In this study we found maternal fasting glucose and HDL-cholesterol to be predictors of 
offspring’s birth weight independently of mother’s early pregnancy BMI and weight gain. 
Maternal fasting glucose and 2-h glucose were predictors of neonatal sum of skinfolds, also 
independently of BMI and weight gain. Still, weight gain was the strongest independent 
predictor of both outcomes. Fasting glucose and gestational weight gain were the only risk 
factor variables that were independent predictors for both birth weight and sum of skinfolds in 
the offspring. Furthermore, the effect of mother’s early pregnancy BMI on birth weight was 
stronger in non-Europeans than in Europeans. 
Mid-gestational weight gain may be more important than subsequent hyperglycaemia in the 
mother in predicting offspring’s birth weight and subcutaneous fat. 
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5 DISCUSSION 
5.1 METHODOLOGICAL CONSIDERATIONS 
5.1.1 Inference of epidemiological studies 
The inference of epidemiological studies is compromised by the presence of random errors, 
systematic errors and confounding. Observational studies will contain all three. Random 
errors can be reduced by a high degree of accuracy. Data collection will, however, always 
entail errors. Random errors make the results imprecise, create noise and make it harder to 
detect differences and thereby result in low reliability. Since the net effect of random errors 
will be close to zero, the results will reflect reality adequately, although it may reduce the 
statistical power and increase the risk of making statistical type 2 errors. Systematic errors, 
also known as bias, can be reduced by choosing gold standard methods. Presence of 
systematic errors may produce false mean values or effect estimates. If we are not aware of 
the systematic errors present in our material we may therefore draw the wrong conclusions. 
While random errors principally affect the statistical power and can be dealt with by 
increasing the sample size, bias will affect the internal validity of the data independently of 
the sample size. Control over potential bias is therefore crucial to secure internal validity and 
to interpret the results correctly.  
A confounding variable is associated with both the dependent and the independent variable. 
Confounding in observational studies is often dealt with by adjusting for potential 
confounders. However, adjustment for confounders is not synonymous with ruling out their 
effect entirely, and sensitivity analyses should therefore be performed in addition to 
adjustments to reduce risk of residual confounding 166. In addition, observational studies 
cannot rule out the possibility of the effect being a result of unmeasured confounding. This is 
why randomized controlled studies are considered among the best to investigate causality, as 
they circumvent the problem of confounding. Due to random errors, bias and confounding 
within epidemiological studies they cannot single-handedly prove causal relationships, but 
causality may be assumed when the Bradford Hill criteria (Table 8) are satisfied 167.  
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Table 8. The Bradford Hill criteria 167 
1) Strength of the association 
2) Consistency across several studies 
3) Specificity of the association,  
4) Temporal relationship 
5) Biological gradient (i.e. dose-response) 
6) Plausible mechanism 
7) Coherence between observational studies and laboratory findings 
8) Experiments supports the finding 
9) Analogy – causality may be assumed if causation have been established for very 
similar cause and disease relationships 
 
Random errors, bias and confounding will be discussed in the following sections. 
5.1.2 Ethnicity 
Bhopal defines ethnicity as a “multi-faceted quality that refers to the group to which people 
belong, as a result of certain shared characteristics, including geographical and ancestral 
origins, but particularly cultural traditions and languages” 168. Ethnicity is complex, and is not 
easily described with a simple label. However, the exploration of why some ethnic groups 
have higher risk of disease has proven to be valuable in medical research 162,169.   
Ethnicity may be classified  in several ways, and when used in epidemiological research, none 
are without limitations 162. How to classify ethnicity depends largely on the aim of the study 
162, as geographical belonging may have a large impact on genetics, while belonging to a 
culture may have a large impact on dietary habits and other lifestyle choices. Also, large and 
heterogenic ethnic groups may hold large variations in country of birth, religion, dietary 
habits, physical activity and other variables that are related to health or disease 162. We 
defined ethnicity as country of birth or mother’s country of birth if born outside of Europe or 
North America, which is considered an objective but crude method for classification of 
ethnicity 162.  
As a country may comprise heterogenous populations, the use of country of birth may mask 
some of the potential relationships with health and disease. Also, the father’s country of origin 
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may influence the offspring’s health, which was not explored in this thesis. As this thesis 
aimed to explore differential relationships across ethnic groups between maternal factors, risk 
of GDM and the effect on birth weight and neonatal subcutaneous fat, we believe that the use 
of countrty of birth was the most appropriate way to define ethnicity in this thesis. Our aim 
was not to assess ethnic differences in dietary habits and physical activity, which is largely 
influenced by culture.  
Merging of countries into ethnic groups may give heterogeneous groups, which in turn may 
lead to misleading results, such as neutralizing of effects. To diminish the risk of neutralizing 
effects, we examined the results using smaller and more homogeneous ethnic groups, but we 
cannot completely rule out this effect.  
Health literacy is likely to differ across ethnicity, and although all questionnaires were 
interviewer-administered by trained study personnel, allowing possible misconceptions to be 
addressed immediately, we cannot rule out the possibility of ethnic groups understanding the 
questions differently. 
5.1.3 Internal validity 
Bias will compromise the internal validity, but if we are aware of potential bias it may help us 
to interpret the results more correctly. 
Selection bias 
The Groruddalen area of Oslo covers both affluent and more deprived areas 159, and the 
participating women had lower education compared to the general population of Oslo. The 
attendance rate was satisfying within all ethnic groups, but varied slightly across the ethnic 
groups. Ethnic Norwegian individuals with low socio-economic status are generally known to 
decline participation based on experience from several studies, while in the remaining ethnic 
groups we do not know who will decline to participate. However, all social leagues seem to 
be represented in all ethnic groups in our sample, which is reassuring. 
In paper 1, we did not find any differences between those included and those excluded. In 
paper 2, we found that those who attended all three visits were more likely to be nulliparous 
and to have a lower BMI. However, since parous women were well represented, and all 
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categories of BMI were represented, we do not believe that this slight selection will affect the 
generalizability of our results considerably. In paper 3, a higher proportion of the excluded 
women were single and originated from South or Central Africa. This is probably because we 
excluded the six women who were included after 24 weeks’ gestation, whereof 4 were from 
South or Central Africa. Women from Africa met for antenatal care later than women from 
the other ethnic groups. We do not believe that this slight selection will affect the 
generalizability of our results considerably.  
Skinfold measurements were missing for 187 neonates, mostly due to delivery not being 
reported to study staff within 72 hours. However, the missing skinfold measurements seemed 
to be completely at random, as we did not find any difference in background variables 
between those with and without skinfold data. 
Information bias 
Maternal anthropometrics 
Although the validity of BIA scales is known to vary across ethnic groups, we used fat mass 
and central fat mass estimated by a BIA scale. However, we used the intra-individual change, 
letting each participant be its own control, and bias is therefore thought to be minimal. 
In paper 1 we adjusted for BMI, although it probably reflects a different degree of adiposity 
and diabetes risk across ethnic groups. However, we found no indications of this introducing 
bias when exploring interactions between Asians and ethnic-specific cut-off levels for BMI 
The pre-pregnancy BMI was based on self-reported pre-pregnancy weight. Self-reported 
weight is generally highly subject to response bias. Obese women have been found to 
underestimate their body weight 170.  The validity of self-reported weight have also been 
found to vary across socio-economic groups 171 and across ethnicity 172. As the women were 
asked about their pre-pregnancy body weight shortly after being weighed, this may have 
reduced the risk of response bias. However, as the perceptions of what is a healthy body 
weight and the general attention given to body weight may differ across ethnic group and 
culture, the accuracy of the self-reported body weight may differ across ethnic groups in our 
data.  
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To explore potential bias in the self-reported body weight prior to pregnancy, we explored the 
difference between the self-reported pre-pregnancy body weight and the measured body 
weight at Visit 1 (Figure 5).  
 
Figure 5. Change in body weight from pre-pregnancy (self-reported) to Visit 1 (measured) across ethnic groups 
and pre-pregnancy BMI.  
 
We did not find any significant ethnic differences in weight change from self-reported pre-
pregnancy up to 15 weeks’ gestation at Visit 1. However, we found a tendency towards higher 
weight gain among Middle Easterners with BMI  ≥  25 kg/m2 (P across ethnic groups 0.075 
(Figure 5). We also found women with BMI ≥ 25 kg/m2 to have a lower weight change from 
pre-pregnancy to Visit 1 than women with BMI less than 25 kg/m2  (P = 0.016). This is, 
however, probably not a result of bias as overweight and obese women are expected to gain 
less weight during pregnancy than normal weight and underweight women. Also, our 
observation would imply that overweight and obese women overestimated their weight, while 
overweight and obese generally tend to underestimate their weight 170. 
The maternal skinfold measurements had relatively large inter-rater variability, although this 
is not uncommon in epidemiological studies 38. The use of composite variables, such as sum 
of skinfolds, have been found to even out potential bias 38. Although there was no indication 
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of bias related to the large inter-rater variability 161, the high presence of random errors may 
weaken our power to detect potential associations with the outcomes tested.   
Although use of MRI might have given more precise estimation of body fat and central fat, 
use of MRI probably would have compromised the participation rate, as the data collection 
would have demanded appearance at a hospital, instead of the community based approach, 
meeting the women where they receive conventional care.   
Glucose and GDM 
The measurement of glucose is not thought to differ in accuracy across ethnicity. Glucose 
levels measured in central laboratories are prone to give falsely low glucose levels due to pre-
analytic glycolysis 173. The ultimate goal of the STORK Groruddalen study was to estimate 
the prevalence of GDM in the population, and a falsely low content of glucose would give a 
falsely low prevalence of GDM. The GDM diagnosis was therefore based on glucose values 
from HemoCue. HemoCue may, however, give falsely low glucose levels relative to the 
triglyceride content 174. A study concluded that if triglycerides were > 3.0 mmol/l, they might 
interfere with HemoCue measured glucose 174. However, in our data, triglycerides seemed to 
interfere with glucose measured by HemoCue in a linear manner (Table 9). As pregnant 
women have higher triglyceride levels than non-pregnant women, this interaction is even 
more topical in our data. The choice of measurement method was therefore crucial in relation 
to the interpretation of findings.  
 
Table 9. Difference in glucose levels measured with HemoCue and Vitros across quartiles of 
triglycerides. 
Quartiles of fasting triglyceride levels (mmol/l) 
1 2 3 4 
  (0.52-1.48) (1.49-1.87) (1.88-2.34) (2.34-5.60) P1 
HemoCue-Vitros (mmol/l) 
ΔFasting glucose 0.53±0.45 0.49±0.41 0.41±0.35 0.23±0.46 <0.001 
Δ2-hour glucose 0.70±0.66 0.60±0.64 0.34±0.51 0.20±0.55 <0.001 
Δ Fasting glucose is the difference in glucose levels measured with the two methods (HemoCue minus Vitros) 
Δ 2-hour glucose is the difference in glucose levels measured with the two methods (HemoCue minus Vitros) 
1 ANOVA 
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The GDM variable, used as outcome in Paper 1 and 2, was based on glucose data analyzed 
with HemoCue. High triglyceride levels may have resulted in falsely low glucose levels, and 
thereby potentially a falsely low prevalence of GDM. However, the objectives in paper 1 and 
2 were to explore whether weight gain or early pregnancy adiposity were risk factors for 
GDM, and not to estimate the true GDM prevalence. Interference between triglycerides and 
glucose levels in the analyses may, however, have weakened the strength of the associations 
in paper 1 and 2, as triglycerides levels were slightly higher in overweight and obese than in 
underweight or normal weight women.  
In paper 3, we wanted to explore how maternal glucose and lipid levels influenced the birth 
weight and subcutaneous fat of the newborn offspring. As triglycerides were included in the 
regression model, we believe that using HemoCue values in this paper would bias the results, 
while Vitros values would give a more correct picture of the relationship between maternal 
glucose and offspring’s birth weight and subcutaneous fat. Falsely low glucose values 
measured with the Vitros method will not change any of the relationships, although it is 
important to be aware that the observed glucose values may be too low. 
The WHO 2013 GDM criteria demands the use of one or more abnormal glucose values 
(fasting, 1-hour or 2-hour glucose). If we had the 1-h glucose value available, the prevalence 
of GDM would probably be slightly higher. This may further contribute to a falsely low GDM 
prevalence, which also may weaken the strength of our associations. 
Neonatal characteristics 
Although the inter-rater variability for skinfold measurement was lower in the neonates than 
in the mothers, it was still relatively high. Again, we did not find any indications of bias, but 
the random errors may give imprecise measurements which, in turn, may weaken potential 
associations with the risk factor variables tested. 
5.1.4 Confounding 
Although we have adjusted for a selection of possible confounders that were measured in our 
cohort, and have performed sensitivity analyses to limit confounding, there will always be 
potential confounding in observational studies. BMI, GDM, weight gain, weight retention and 
growth of the foetus will all be influenced by maternal energy balance and thus maternal 
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physical activity and diet. Another important possible confounder to the ethnic differences in 
GDM is socio-economic position, which has been related to ethnic health differences in 
several studies. Socio-economic position is also highly related to lifestyle factors such as diet 
and physical activity. However, the objective of the three papers were not to explore whether 
diet, physical activity or socio-economic position explained the ethnic differences in 
adiposity, weight gain etc., but to explore whether ethnic differences in adiposity were able to 
explain some of the ethnic difference in risk of GDM, and whether the effects of maternal 
glucose, lipids and weight gain on offspring’s birth weight and subcutaneous fat differed 
across ethnic groups. 
5.1.5 Study design 
The STORK Groruddalen study is a population-based prospective cohort study. Prospective 
cohort studies limit the risk of recall bias and reverse causation, but are at high risk for 
confounding. Still, a prospective cohort study was considered an appropriate study design to 
study risk factors associated with GDM across ethnic groups, as GDM is a quite prevalent 
outcome. The population-based design strengthens the external validity of the findings. 
5.1.6 External validity 
The sample should be representative for the main ethnic groups of pregnant women living in 
Groruddalen. Since the internal validity has been accounted for and the results have been 
interpreted with respect to potential bias, the findings of this thesis should be generalizable to 
pregnant women of the described ethnic groups, living in Norway. Since the effects of 
maternal adiposity and mid-gestational weight gain were independent of ethnicity, their 
relationship with GDM and neonatal anthropometry will probably be generalizable to other 
populations of healthy pregnant women.  
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5.2 DISCUSSION OF MAIN FINDINGS 
5.2.1 Paper I – mid-gestational weight and fat gain and risk of GDM  
We did not find any ethnic differences in weight gain. However, as the IOM 
recommendations for weight gain do not take ethnicity into account although they use pre-
pregnancy BMI to classify maternal adiposity, the IOM recommendations may not be 
adequate for all ethnic groups, especially Asians. Due to a higher degree of adiposity for the 
same BMI in Asians, the recommended weight gain may be too high for Asians. 
Our results suggested that central fat gain from 15 to 28 weeks’ gestation was a stronger risk 
factor for GDM than weight gain and total fat gain. Thereby, central adiposity may be of 
importance also in relation to GDM. This finding fits well with the hypothesis that ectopic fat 
accumulation may play a central role in the development of diabetes. Our findings also fit 
well with the idea of a relationship between central adiposity and hepatic insulin resistance as 
the WHO 2013 GDM criteria especially capture those with elevated fasting glucose, 
characteristically associated with hepatic insulin resistance.  
In paper 1, we showed that the effects of weight, total and central fat gain on GDM remained 
after adjusting for HOMA-IR in early pregnancy. However, insulin resistance explained some 
of the ethnic differences in GDM risk, especially among South Asians, indicating that at least 
some of the ethnic differences in GDM risk may be due to differences in insulin resistance in 
early pregnancy.  Insulin resistance in early pregnancy did, however, not entirely explain the 
higher GDM risk in South Asians. Since HOMA-IR is not the gold standard and merely an 
indicator of insulin resistance, we cannot rule out that the remaining higher risk for GDM 
among South Asians is due to differences in insulin resistance. In fact, studies using gold 
standard methods for assessing central adiposity and insulin resistance found that central 
adiposity, as well as general adiposity, contributed greatly to the metabolic disturbances 
observed in South Asian men, especially to the increased insulin resistance 175 176. Hence, 
finding the reason to the increased insulin resistance in the non-Western ethnic groups may be 
important in finding explanations for the ethnic differences in GDM and T2DM risk. One 
study found higher levels of liver fat in South Asians than “Caucasians” 177, which may 
explain their observed higher insulin resistance.  
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One study showed that short term intake of a high fat high calorie diet induced insulin 
resistance in South Asians, but not in “Caucasians” 178, indicating that there might be ethnic 
differences in how well different diets are tolerated. As many South Asians tend to adopt a 
Westernized version of their traditional diet 179, this could be one reason to why South Asians 
have a higher risk of GDM and T2DM.  
5.2.2 Paper II – ethnic differences in subcutaneous fat and s-leptin 
and GDM 
In paper 2 we found higher amounts of subcutaneous fat, as measured with skinfolds, in South 
Asians than in Europeans, despite a lower BMI. Two of these skinfolds, subscapular and 
suprailiac, are more closely associated with central adiposity 65 and thereby suggest that the 
South Asian women in our study had more central adiposity than Europeans. However, 
studies using the gold standard methods for measuring central adiposity differ in their 
findings. One study found no difference in superficial or deep subcutaneous fat or central 
adiposity between Pakistanis and Norwegians 180, although statistical type 2 errors cannot be 
ruled out due to small numbers. One study found higher levels of deep subcutaneous fat in 
South Asians than in Europeans 181  while another study found lower levels of superficial 
subcutaneous fat in South Asians than in “Caucasians” 177.  
We found higher s-leptin levels for a given BMI in South Asians, supported by several others 
53,54,182,183. The higher s-leptin observed in South Asians could be a further indication of poor 
measurement techniques for adiposity, as s-leptin is known to reflect fat mass. However, there 
are other possible explanations to the higher s-leptin observed in South Asians.  
A higher secretion of leptin could be caused by hypertrophic adipocytes 184. South Asians 
have been found to have larger adipocytes than “Caucasians” 177,185, and hypertrophic 
adipocytes have, in turn, been associated with insulin resistance 184,186,187 and T2DM 186. The 
kidneys account for approximately 80 % of leptin removal from plasma 188. However, leptin 
clearance do not seem to increase in obese individuals, resulting in a lower fractional removal 
rate with increasing leptin levels 188, which partly may explain the high s-leptin levels 
observed in obese individuals. South Asians with T2DM have been found to have a higher 
incidence and faster progression of renal disease 189. Although highly speculative and not yet 
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studied, South Asians may have a lower renal function which in turn may lead to reduced 
leptin clearance, which could explain their higher s-leptin. 
Banks and co-workers convincingly found that high triglyceride levels, either induced by 
starvation or diet-induced obesity, decreased transport of leptin across the blood-brain barrier, 
and treatment with gemfibrozil reversed both the hypertriglyceridaemia and the reduced leptin 
transport across the blood-brain barrier in mice 190. If leptin is not transported across the 
blood-brain barrier it may not induce satiety, which may explain the paradox of high s-leptin 
levels in obese as they often have elevated triglyceride levels. As higher triglyceride levels 
have been observed in South Asians compared to Europeans 130-132, it is possible that South 
Asians have reduced leptin transport across the blood-brain barrier and thereby reduced 
satiety. Also, the concentration of soluble leptin receptor seems to be important in 
bioavailability of leptin, as low levels of the soluble leptin receptor are associated with 
obesity 43,191,192. Weight loss, on the other hand is associated with an increase in the soluble 
leptin receptor concentration 43,193. A strong inverse association has been found between 
plasma soluble leptin receptor levels and T2DM 194 . Although scarcely explored, a study 
found ethnic differences in the concentration of soluble leptin receptor, with lower levels 
observed in Japanese and Chinese compared with “Caucasian” women 195. Soluble leptin 
receptor levels in South Asians have, to my knowledge, not been studied. 
Hence, the high s-leptin observed in South Asians may be a result of several mechanisms, 
such as hypertrophic adipocytes, lower leptin clearance, differences in soluble leptin receptor 
or simply due to high amounts of fat relative to low amounts of lean mass and body size.  
5.2.3 Paper III – effects on offspring’s birth weight and 
subcutaneous fat 
Mid-gestational weight gain was a stronger predictor of both birth weight and subcutaneous 
fat in the newborn than maternal glucose or lipids. The excessive weight gain is an indication 
of maternal energy excess, and the energy excess is most likely transferred to the foetus to 
some extent. There are several ways in which the foetus receives energy from the mother, 
such as through amino acids, NEFAs, ketone bodies or other substrates in addition to the 
substrates measured in our study. However, although our study cannot designate the exact 
mechanisms in which weight gain affects neonatal anthropometry, our study shows that mid-
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gestational weight gain may be a better predictor of birth weight and neonatal subcutaneous 
fat than maternal glucose, lipid levels, or pre-pregnancy BMI. 
We used birth weight and neonatal sum of skinfolds as proxy outcomes for future health. 
Although there is some evidence suggesting that high birth weight increases risk for adult 
overweight and T2DM 152,153, the long-term effects of high amounts of subcutaneous fat in the 
newborn seem to be poorly studied. However, offspring of diabetic mothers—which are 
generally born with more adipose tissue than offspring of non-diabetic mothers—have 
increased risk of obesity and diabetes in adulthood 15. Also excessive maternal weight gain 
has been associated with poor adult health in the offspring 72. Whether this is due to increased 
neonatal adiposity, however, is not fully explored. 
In accordance with the developmental overnutrition hypothesis 91, Dabelea and Crume 196 
express their concern that maternal pre-existing weight and weight gain during pregnancy 
may “generate an intergenerational vicious cycle of obesity and diabetes because heavier 
mothers give birth to heavier daughters, who are at increased risk to be obese themselves 
during their reproductive years, thus perpetuating the cycle” 196. The vicious cycle of obesity 
and diabetes may therefore be enforced by pre-existing overweight and obesity, excessive 
weight gain during pregnancy and GDM, which may increase the risk of overweight, obesity 
and diabetes in the adult offspring.  
Epigenetic changes in the foetus in response to maternal exposure have been proposed as 
potential mechanisms for intrauterine programming. Very little research in this field has been 
performed in humans, and most studies that supports an epigenetic role in programming of the 
foetus has been as a result of undernutrition. 
5.2.4 Public health implications 
The high level of adiposity, the high mid-gestational weight gain and their relationship with 
risk of GDM, birth weight and neonatal subcutaneous fat, suggest a great potential for 
prevention. In light of the developmental overnutrition hypothesis, ethnic differences in 
GDM, and weight and fat retention after delivery may contribute to ethnic differences in poor 
health, as the exposed offspring may be at higher risk of obesity and diabetes than the un-
exposed. We did not find ethnic differences in mid-gestational weight gain, but prevention of 
excessive weight gain may still reduce the risk of GDM and the birth weight and 
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subcutaneous fat of the offspring. The higher amounts of subcutaneous fat and s-leptin in 
South Asians explained some of the higher GDM risk in South Asians than in Europeans. 
Randomized trials have shown that treatment of GDM reduces neonatal fat mass, birth weight 
and macrosomia 197,198, perinatal morbidity 197, and also improve maternal outcomes 197,198. A 
recent study found no reduction in childhood obesity or metabolic dysfunction when studying 
long-term effects in offspring born to mothers who developed GDM 199, although they found 
an effect on neonatal measurements. However, as the authors mention, the study was probably 
statistically under powered 199.  
Although the IADPSG criteria has been criticized for labelling a large proportion of pregnant 
as ill, a recent study concluded that application of the IADPSG criteria significantly reduced 
adverse pregnancy outcomes and proved cost-effective compared to the conventional 
Carpenter-Coustan criteria, despite a 3.5 fold increase in GDM prevalence 200. This finding 
indicates that detection of less severe hyperglycaemia and offering lifestyle advice to manage 
the hyperglycaemia may improve health for both the mother and her offspring. Since GDM is 
such a prevalent outcome, detection and management of GDM may thus have a large impact 
on the public health. 
Studies exploring the effect of lifestyle interventions on weight gain and maternal and foetal 
outcomes have given different results. Thangiratinam 201 found in a meta-analysis of 
randomized controlled trials that among lifestyle interventions on maternal weight and 
obstetric outcomes, dietary interventions seem to be the most successful 201. Physical activity 
interventions, on the other hand, seem to be less effective 202. Dietary intervention during 
pregnancy significantly reduced weight gain in pregnancy, GDM, pre-eclampsia, gestational 
hypertension and preterm delivery for the mother 201. For the offspring, dietary intervention 
during pregnancy reduced risk of shoulder dystocia and border significantly reduced risk of 
intrauterine death 201. Two recent randomized controlled trials confirmed that lifestyle 
intervention during pregnancy may reduce gestational weight gain 203,204. Other randomized 
controlled trials have showed that low intensity intervention successfully limited postpartum 
weight retention 205,206. Although there are some indications pointing towards a benefit from 
lifestyle interventions during pregnancy, the clinical trials to explore the effect of lifestyle 
interventions on weight gain and other obstetric outcomes are few, heterogeneous and 
criticized of being of poor quality 207. Intervention trials exploring the effect of weight loss in 
overweight and obese women prior to conception on obstetric outcomes are lacking.  
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5.2.5 Ethical hesitations to recommending weight loss 
The findings in this thesis suggest that promoting a healthy pre-pregnancy body weight and a 
healthy weight gain during pregnancy, may reduce risk of GDM, high birth weight and 
neonatal adiposity. However, for the past years, there has been a debate concerning whether 
overweight and obesity per se is detrimental to health, as a systematic review and meta-
analysis suggested that overweight may be protective in relation to morbidity and mortality 
208. Further, a study concluded that being labelled as overweight or obese during adolescence 
was a significant predictor of future risk of obesity, independently of BMI at time of weight 
labelling 209, suggesting that stigmatization may be more detrimental than the excessive 
weight per se.  
However, several studies have busted the myth that metabolically healthy obesity exists 210-
214. Although metabolically healthy obese individuals have lower risk of morbidity and 
mortality than their metabolically unhealthy counterparts, the metabolically healthy obese 
individuals have increased risk of diabetes 210-213 and cardiovascular disease 212 compared to 
metabolically healthy normal weight individuals.  
As weight loss, and especially long-term maintenance of weight loss, is difficult, there are 
concerns to whether a focus on weight loss will improve health, especially since some studies 
suggest that weight fluctuation, results in higher morbidity and mortality 215-217. However, a 
study found that these associations between weight fluctuation, morbidity and mortality were 
attributed to disadvantageous lifestyle and pre-existing disease rather than the weight 
fluctuation itself 218. Either way, avoiding the initial development of obesity seems at present 
the best way to avoid the associated morbidity and mortality. 
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6 CONCLUSIONS 
x Women of European, South Asian, Middle Eastern, African and East Asian origin 
experienced similar mid-gestational weight gain 
x Mid-gestational weight gain, especially gain of central fat, was positively associated 
with increased risk of GDM 
x Early pregnancy BMI, subcutaneous fat and leptin were all positively associated with 
increased risk of GDM 
x Women of South Asian origin had more subcutaneous fat and higher s-leptin for the 
same BMI as Europeans 
x Women of South Asian origin retained more weight and fat after delivery than 
Europeans, potentially leaving them at even higher risk of GDM in future pregnancies 
x Maternal glucose and lipid levels were positively associated with offspring’s birth 
weight and subcutaneous fat  
x Mid-gestational weight gain explained some, but not all, of the effect of glucose and 
lipids on offspring’s birth weight and subcutaneous fat 
x Mid-gestational weight gain was a stronger predictor of both birth weight and 
Maternal adiposity did not fully explain why some ethnic groups, especially South Asians, 
have a higher risk of GDM, but ethnic differences in insulin resistance in early pregnancy 
may play an important role.  
Prevention of overweight and obesity in women of fertile age would probably be of major 
public benefit with regards to the future health of the mothers and their babies. The stronger 
effect of mid-gestational weight gain than maternal glucose or lipids on offspring 
anthropometry, suggest that preventing excessive mid-gestational weight gain may be more 
important than preventing GDM. However, they generally depend on the same preventive 
strategies, with a healthy diet without energy excess and increased physical activity. 
Pregnancy is often considered a window of opportunity to attain a healthy lifestyle, as 
pregnant women generally are highly susceptible to lifestyle advice. Health workers probably 
should have a larger focus on a healthy weight gain during pregnancy to reduce the risk of 
GDM and its consequences, as well as emphasize the importance of avoiding weight retention 
after pregnancy to secure a good starting point for future pregnancies. 
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7 FUTURE RESEARCH 
Future studies should explore whether total or regional adiposity can explain ethnic 
differences in insulin resistance while using more accurate measurements of fat than in the 
present studies. Especially we suggest to explore whether total and regional adiposity, as well 
as liver fat and pancreatic fat, can explain the insulin resistance, as measured by 
hyperinsulinaemic euglycaemic clamp, across ethnic groups.  
Soluble leptin receptors seem to be protective of T2DM, and are inversely associated with 
adiposity. Future research should explore whether ethnic differences in soluble leptin receptor 
are present, and whether ethnic differences in soluble leptin receptor can predict the higher 
GDM risk in South Asians. Levels of soluble leptin receptors or the ratio between soluble 
leptin receptors and s-leptin, may be more precise predictors of GDM or T2DM risk than s-
leptin isolated, especially across ethnicity. 
It would be interesting to explore whether epigenetic modifications of maternal and/or foetal 
tissues may explain the transfer of maternal adiposity and weight gain to the foetus 
Few studies have explored the long term health consequences of being born with large 
amounts of subcutaneous fat, and this may be addressed through long-term follow-up of well-
characterized birth cohorts.  
Finally, intervention studies in multi-ethnic cohorts of pre-pregnant women or women in early 
pregnancy to improve physical fitness and reduce overweight and obesity would be of high 
value.  
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